Posted on

Largest psilocybin study continues to grow

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

The world’s largest psilocybin therapy study on depression is approaching completion, and it’s even bigger than expected.

Compass Pathways (CMPS) announced that it’s close to completing its phase 2b trial on treatment-resistant depression, and expects to report the findings by the end of this year. So far, 233 patients have received COMP360 psilocybin therapy, exceeding the target of 216. The company also announced its Q2 financial highlights including $316.3 million in cash and equivalents as of June 30.

PDF of article

Posted on

If you missed the cannaBUS, jump on the psilocybin train

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More

Now is the time to buy these 10 psychedelic stocks.

When the cannabis company GW Pharmaceuticals sold for billions earlier this year, those who didn’t invest were left with major regret. If you missed out on cannabis, now is your chance to be an early investor in the shroom boom as psychedelic companies begin to follow a similar pathway. These 10 companies are worth the buy according to Maxim Group’s latest analysis.

PDF of article

Posted on

Compass Pathways conducts world’s largest psilocybin therapy trial

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression

Move over Prozac, Compass Pathways (CMPS) just made major progress in psychedelic treatment for depression. The company is conducting the world’s largest psilocybin therapy trial for its proprietary psychedelic compound, COMP360, which targets treatment-resistant depression. So far, 216 patients have had psilocybin therapy sessions at Compass’s 22 trial sites across 10 countries, with 14 more patients completing sessions over the next two weeks. Researchers will follow-up with each patient 12 weeks after the sessions and will publish the findings by the end of this year. Other studies have found that psilocybin is 4 times more effective than typical antidepressants – let’s see what Compass’s new research reveals.

Posted on

Investor became a billionaire after a psilocybin trip lead him to a new investment strategy

How Taking Magic Mushrooms Led To A Billion Dollar Fortune

After abstaining from drugs for decades, a German investor, Christian Angermayer, went on a life-changing mushroom trip that left him with profound insights and even made him understand Bitcoin. It was then that Angermayer decided to make radical changes to his investment strategy by focusing on things he’s passionate about.

During a second transformative mushroom trip, Angermayer had the idea to commercialize psychedelics, which led him to make an angel investment in Compass Pathways, a biotech company focused on psychedelic therapy. His stake in Compass Pathways is now worth $2 billion and he manages over $2.5 billion in assets.

PDF of article

Posted on

Shark Tank’s Kevin O’Leary says investing in psychedelics has far more potential than cannabis

7 Investment Tips from Kevin O’Leary, Who Says There’s More Money In Psychedelics Than There Is In Cannabis

At a CNBC healthcare summit, Shark Tank venture capitalist Kevin O’Leary said that “the potential of psychedelics far exceeds the potential of cannabis”. O’Leary believes that the size and scale of the psychedelics market is appealing because of the lack of advancements in mental health treatment over the past several decades. O’Leary currently invests in MindMed and Compass Pathways, and advises investors to hold stakes in companies with multiple clinical trials.

PDF of article